FDASIA Has Low Profile in Pharma Earnings Calls
This article was originally published in RPM Report
Executive Summary
In the wave of pharma earnings calls after the July 9 signing of the FDA Safety & Innovation Act, the good news is that the law did not appear to be a material event for most companies and investors. The lack of attention to the law by management teams and analysts is a quiet reaffirmation that this iteration of the user fee reauthorization went smoothly for industry and the regulatory agency.